We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+37.28%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$959M
AUM Growth
+$88.6M
Cap. Flow
-$54.3M
Cap. Flow %
-5.67%
Top 10 Hldgs %
33.04%
Holding
103
New
15
Increased
39
Reduced
35
Closed
12

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$17.6M
2
BSX icon
Boston Scientific
BSX
+$15.7M
3
KALV
KalVista Pharmaceuticals
KALV
+$14.6M
4
MCK icon
McKesson
MCK
+$7.81M
5
FOLD
Amicus Therapeutics
FOLD
+$7.68M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$18.7M
2
LLY icon
Eli Lilly
LLY
+$17.3M
3
THC icon
Tenet Healthcare
THC
+$16.8M
4
RVTY icon
Revvity
RVTY
+$15.2M
5
COO icon
Cooper Companies
COO
+$14.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TERN
51
DELISTED
Terns Pharmaceuticals
TERN
$7.02M 0.73%
934,760
+116,952
+14% +$747K
PGEN icon
52
Precigen
PGEN
$2.45B
$6.91M 0.72%
2,101,715
+558,892
+36% +$1.58M
SDGR icon
53
Schrodinger
SDGR
$1.39B
$6.82M 0.71%
340,187
-247,369
-42% -$4.97M
BMRN icon
54
BioMarin Pharmaceuticals
BMRN
$13.6B
$6.82M 0.71%
125,949
-99,201
-44% -$5.67M
CERT icon
55
Certara
CERT
$1.22B
$6.74M 0.7%
551,850
+51,850
+10% +$567K
ASMB icon
56
Assembly Biosciences
ASMB
$536M
$6.43M 0.67%
+250,981
New +$5.51M
OM icon
57
Outset Medical
OM
$84.6M
$6.42M 0.67%
454,512
-94,540
-17% -$1.47M
NSPR icon
58
InspireMD
NSPR
$40.3M
$5.88M 0.61%
2,440,633
+1,205,328
+98% +$2.92M
STOK icon
59
Stoke Therapeutics
STOK
$2.13B
$5.88M 0.61%
+250,000
New +$4.28M
IQV icon
60
IQVIA
IQV
$39.8B
$5.7M 0.59%
30,000
-79,500
-73% -$14.5M
TMCI icon
61
Treace Medical Concepts
TMCI
$309M
$5.69M 0.59%
847,675
+3,677
+0.4% +$24K
SIBN icon
62
SI-BONE Inc
SIBN
$852M
$5.57M 0.58%
378,583
+16,575
+5% +$271K
MAZE
63
Maze Therapeutics
MAZE
$1.52B
$5.19M 0.54%
+200,000
New +$3.38M
WGS icon
64
GeneDx Holdings
WGS
$2.46B
$4.88M 0.51%
45,250
-129,750
-74% -$14.1M
ABVX
65
Abivax
ABVX
$10.9B
$4.69M 0.49%
+55,197
New +$3.38M
APGE icon
66
Apogee Therapeutics
APGE
$10.2B
$4.2M 0.44%
105,831
+50,427
+91% +$1.93M
IMNM icon
67
Immunome
IMNM
$3.17B
$4.11M 0.43%
+351,131
New +$3.49M
PTGX icon
68
Protagonist Therapeutics
PTGX
$9.84B
$4.11M 0.43%
61,849
+253
+0.4% +$14.4K
AGIO icon
69
Agios Pharmaceuticals
AGIO
$2.04B
$4.03M 0.42%
+100,380
New +$3.78M
CVRX icon
70
CVRx
CVRX
$72.7M
$3.97M 0.41%
491,408
-297,691
-38% -$2.24M
MNKD icon
71
MannKind Corp
MNKD
$1.24B
$3.52M 0.37%
656,084
-1,244,834
-65% -$5.46M
RXST icon
72
RxSight
RXST
$294M
$3.42M 0.36%
380,713
-253,161
-40% -$2.22M
SYRE icon
73
Spyre Therapeutics
SYRE
$9.18B
$3.36M 0.35%
+200,753
New +$3.27M
CRNX icon
74
Crinetics Pharmaceuticals
CRNX
$8.96B
$3.07M 0.32%
73,725
+313
+0.4% +$10K
RPID icon
75
Rapid Micro Biosystems
RPID
$84.8M
$3.05M 0.32%
913,443
– –
1 2
3
4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Parkman Healthcare Partners held 103 positions worth $959M, up 10% from $870M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Parkman Healthcare Partners withdrew a net $54.3M in Q3 2025, closing 12 positions and reducing 35 holdings. Its most notable exit was Verona Pharma, an estimated $18.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier.

Against the trend, Parkman Healthcare Partners opened a new position in Biogen worth $18.2M.

  • Parkman Healthcare Partners's largest Q3 2025 buy was Biogen: 130,165 shares worth $18.2M.
  • Parkman Healthcare Partners added most to Boston Scientific in Q3 2025, an estimated $15.7M increase.
  • Parkman Healthcare Partners's biggest Q3 2025 reduction was Eli Lilly, cutting an estimated $17.3M.
  • Parkman Healthcare Partners fully exited Verona Pharma in Q3 2025, selling an estimated $18.7M.
  • Parkman Healthcare Partners's ten largest holdings make up 33% of its $959M portfolio in Q3 2025.
  • Parkman Healthcare Partners opened 15 new positions and closed 12 in Q3 2025.
  • Parkman Healthcare Partners's portfolio value rose 10% quarter-over-quarter to $959M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2025, filed 14 Nov 2025.